Trump Expedites Ibogaine Research for Veterans
Analysis based on 54 articles · First reported Apr 17, 2026 · Last updated Apr 19, 2026
Donald Trump's executive order to expedite research and access to psychedelic drugs like Ibogaine is expected to significantly impact the pharmaceutical and biotechnology sectors. This move could open new avenues for drug development and treatment, potentially leading to increased investment and innovation in psychedelic medicine, despite the inherent risks associated with these substances.
President Donald Trump signed an executive order to accelerate the review and research of psychedelic drugs, particularly Ibogaine, for medical use. This directive aims to ease federal restrictions and spur the development of treatments for conditions like PTSD and opioid addiction, especially benefiting veterans. The United States===Food and Drug Administration is tasked with expediting drug reviews, issuing national priority vouchers for three psychedelics, and initiating human trials for Ibogaine. Donald Trump also pledged $50 million in federal funding for Ibogaine research, building on efforts by figures like podcaster Joe Rogan and former United States===Texas_Governor Rick Perry, who have advocated for the drug. While proponents highlight its potential, concerns remain regarding Ibogaine's known cardiovascular toxicity, which led the United States===National Institutes of Health to discontinue research in the 1990s. Despite these risks, the order marks a significant shift in the United States' approach to psychedelic medicine, potentially encouraging further state-level funding and research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard